Literature DB >> 22742992

Tau protein kinases: involvement in Alzheimer's disease.

Ludovic Martin1, Xenia Latypova, Cornelia M Wilson, Amandine Magnaudeix, Marie-Laure Perrin, Catherine Yardin, Faraj Terro.   

Abstract

Tau phosphorylation is regulated by a balance between tau kinase and phosphatase activities. Disruption of this equilibrium was suggested to be at the origin of abnormal tau phosphorylation and thereby might contribute to tau aggregation. Thus, understanding the regulation modes of tau phosphorylation is of high interest in determining the possible causes at the origin of the formation of tau aggregates in order to elaborate protection strategies to cope with these lesions in Alzheimer's disease. Among the possible and specific interventions that reverse tau phosphorylation is the inhibition of certain tau kinases. Here, we extensively reviewed tau protein kinases, their physiological roles and regulation, their involvement in tau phosphorylation and their relevance to AD. We also reviewed the most common inhibitory compounds acting on each tau kinase.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22742992     DOI: 10.1016/j.arr.2012.06.003

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  165 in total

1.  FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease.

Authors:  Waltraud Mair; Jan Muntel; Katharina Tepper; Shaojun Tang; Jacek Biernat; William W Seeley; Kenneth S Kosik; Eckhard Mandelkow; Hanno Steen; Judith A Steen
Journal:  Anal Chem       Date:  2016-03-07       Impact factor: 6.986

2.  Formaldehyde, Epigenetics, and Alzheimer's Disease.

Authors:  Fei Wang; Danqi Chen; Peipei Wu; Catherine Klein; Chunyuan Jin
Journal:  Chem Res Toxicol       Date:  2019-04-19       Impact factor: 3.739

3.  Loss of the m-AAA protease subunit AFG₃L₂ causes mitochondrial transport defects and tau hyperphosphorylation.

Authors:  Arun Kumar Kondadi; Shuaiyu Wang; Sara Montagner; Nikolay Kladt; Anne Korwitz; Paola Martinelli; David Herholz; Michael J Baker; Astrid C Schauss; Thomas Langer; Elena I Rugarli
Journal:  EMBO J       Date:  2014-03-28       Impact factor: 11.598

Review 4.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

Review 5.  Three dimensions of the amyloid hypothesis: time, space and 'wingmen'.

Authors:  Erik S Musiek; David M Holtzman
Journal:  Nat Neurosci       Date:  2015-06       Impact factor: 24.884

Review 6.  Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease.

Authors:  Filipa I Baptista; Ana G Henriques; Artur M S Silva; Jens Wiltfang; Odete A B da Cruz e Silva
Journal:  ACS Chem Neurosci       Date:  2014-01-03       Impact factor: 4.418

Review 7.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

8.  1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) Urea, a Selective and Potent Dual Inhibitor of Soluble Epoxide Hydrolase and p38 Kinase Intervenes in Alzheimer's Signaling in Human Nerve Cells.

Authors:  Zhibin Liang; Bei Zhang; Meng Xu; Christophe Morisseau; Sung Hee Hwang; Bruce D Hammock; Qing X Li
Journal:  ACS Chem Neurosci       Date:  2019-08-19       Impact factor: 4.418

Review 9.  Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis.

Authors:  Thomas L Platt; Valerie L Reeves; M Paul Murphy
Journal:  Biochim Biophys Acta       Date:  2013-04-22

10.  IFN-γ promotes τ phosphorylation without affecting mature tangles.

Authors:  Andrew Li; Carolina Ceballos-Diaz; Nadia DiNunno; Yona Levites; Pedro E Cruz; Jada Lewis; Todd E Golde; Paramita Chakrabarty
Journal:  FASEB J       Date:  2015-07-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.